PD-L1 expression

Despite pembrolizumab discontinuation, both patients maintained durable systemic disease control. These cases emphasize the importance of recognizing uncommon radiological patterns such as the atoll sign in patients receiving ICIs, highlighting the need for vigilance even after prolonged therapy and underscoring the potential for sustained oncologic benefit despite treatment discontinuation.

PD-L1 expression is frequently observed in AM with BRAFV600E mutation, whereas no significant correlation is identified between PD-L1 and the clinicopathological parameters associated with AM. Within the limitation of relatively short follow-up duration, high CD8+T cell infiltration was indicated to be potentially correlated with favorable DFS in AM patients, which needs further verification in cohorts with longer follow-up.

In vivo, TMEM160 knockdown suppressed tumor growth, reduced TMEM160-positive and VEGFA-positive proportions, increased interferon-γ (IFN-γ) positivity, and decreased p-PI3K/PI3K and p-AKT/AKT ratios in tumor tissues. These findings supported that TMEM160 might affect VEGFA-associated PI3K/AKT signaling to promote malignant phenotypes in HCC, suggesting TMEM160 as a candidate molecular target for further investigation.

NT5E accelerates disease progression by promoting malignant biological behaviors in colorectal cancer and synergistically shaping an immunosuppressive microenvironment with PD-L1. Its overexpression constitutes an independent adverse prognostic factor. This discovery offers novel insights for anti-PD-1/PD-L1 combination immunotherapy.

Hypoxia upregulated the MSC-AS1/ITGA5 axis and increased VEGFA/PD-L1 expression, along with changes in the migrasome-related protein TSPAN4, suggesting a potential association with migrasome-related molecular features, which requires direct experimental validation. Collectively, our findings establish a novel MRL-based signature for prognostic prediction in HNSCC and highlight the hypoxia-responsive MSC-AS1/ITGA5 axis as a promising target for combinatorial therapeutic strategies.

These findings reveal that geniposide inhibits osteosarcoma through dual mechanisms: Ndufs8-mediated oxidative phosphorylation activation and PD-L1/PD-L1 axis suppression, offering a novel therapeutic strategy. These findings suggest that geniposide is a promising therapeutic agent for osteosarcoma and may enhance the efficacy of immunotherapy combined with PD-L1 blockade.

Consistent with these findings, transcriptomic analyses in PMBCL cohorts linked PDCD1LG2 expression to B-cell identity and signaling modules, whereas CD274 expression aligned with interferon-responsive immune programs. Together, these results support a model in which PD-L1 and PD-L2 associate with distinct immune and lineage-associated states in PMBCL and provide a framework for exploring biologically informed stratification strategies in this disease.

After three cycles of neoadjuvant carboplatin, pemetrexed, and pembrolizumab, computed tomography (CT) scan revealed a significant response. Incorporating a POLE evaluation could improve the integrated decision-making process for patients with NSCLC in the perioperative setting. Prospective studies are warranted to validate this observation.

These findings underscore the potential of autophagy as a therapeutic target and highlight strategies for combining autophagy modulators with conventional treatments to overcome resistance. This article provides a foundation for the development of precision medicine approaches tailored to autophagy-related pathways in gynaecologic malignancies.

We developed and validated an interpretable, [18F]FDG PET/CT-based nomogram integrating SUVmax and clinical-pathological features to non-invasively predict PD-L1 high expression in resectable NSCLC. This study suggests that traditional LR offers comparable predictive accuracy to complex ML algorithms, while providing enhanced clinical transparency and a potential non-invasive adjunct for personalized nCIT decision-making.

Findings on EGFR mutations were consistent with the national and international literature. However, PD-L1 expression rates were higher than those typically reported in Brazilian studies, highlighting regional variation in biomarker prevalence.

Our findings suggest that CD44 may act as a key regulator linking iron metabolism and immune modulation in EBV-associated NPC. Although direct iron measurements were not performed, the observed associations with reduced CD8⁺ T-cell infiltration are consistent with a potential role of CD44 in shaping an immune-restricted tumor microenvironment. These results provide integrative evidence of a CD44-iron-immune axis in a Tunisian NPC cohort and highlight CD44 as a potential prognostic biomarker and therapeutic target.